Eikon Therapeutics presented updated clinical data at the 2026 ASCO meeting showing encouraging results for its EIK1001 drug in first-line treatment of stage 4 non-small cell lung cancer (NSCLC), with a 63.1% response rate and good tolerability. The company also reported positive safety and efficacy data for EIK1003, a PARP1 inhibitor, both as monotherapy and combined with paclitaxel in advanced solid tumors. These results support continued development of these therapies, which aim to improve cancer treatment outcomes. Eikon plans further trials and data releases in 2026 and beyond.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Immuron Limited announced a 6% increase in global sales for FY26, reaching AUD$7.7 million, driven by a 10% rise in Australian sales and significant growth in Canada and the US markets. The growth in Australia is attributed to enhanced digital market...
GRAVITY Co., Ltd. has officially launched Ragnarok: The New World, an open-world MMORPG based on the popular Ragnarok IP, in Southeast Asia on July 16, 2026. The game is available on both Mobile (Google Play and Apple App Store) and PC (official webs...
Zymeworks Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The company will not hold an earnings call following the release due to its pending acquisition of Theravance Biopharma. This acquisition will...
Global Net Lease, Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 5 after the NYSE closes. The company will hold a conference call and webcast on August 6 at 11:00 a.m. ET to discuss the res...
